<DOC>
	<DOCNO>NCT01402648</DOCNO>
	<brief_summary>The decreased Estrogen Receptor beta ( ERβ ) expression non adenomatous mucosa ApcMin/+ mouse favour intestinal neoproliferation . The dietary supplementation blend ERβ agonists lignin show recover ERβ healthy wild type level , reduce polyp number lower dysplasia also observe adenomatous mucosa . In randomised , double blind placebo control study , assess ERβ similarly guide apoptotic control cell proliferation non adenomatous colon mucosa patient affect sporadic adenopolyposis , prone polyp recurrence . For 60 day advance screen colonoscopy , patient supplement dietary blend ERβ agonists lignin ( Eviendep , CM &amp; D Pharma Limited , London , UK ) top common diet ( leave unchanged study period ) , study pro-proliferative behavior non adenomatous mucosa effect . Sixty patient naïve previous concomitant hormonal anti-inflammatory CRC chemoprevention sequentially 1:1 randomise active placebo supplementation . ERα ERβ ( mRNA , Western Blotting , Elisa , immunostaining ) , TUNEL , caspase-3 Ki-67 ( immunostaining ) assess bioptic normal colon mucosa sample . Study power : 80 % , type 1 error : .05 ( two-tails ) . Statistics : Non parametric Wilcoxon test efficacy . MANOVA proliferative apoptotic biomarkers relationship common diet 60 day supplementation .</brief_summary>
	<brief_title>Estrogen Receptor Beta Agonists ( Eviendep ) Polyp Recurrence</brief_title>
	<detailed_description>Enrolled patient actively ongoing surveillance program follow polyp recurrence progression CRC . Eligible patient undergone polypectomy since 2003 , affect multiple polyp &lt; 10 mm one-two adenoma &lt; 10 mm and/or grade dysplasia make classified intermediate risk CRC , schedule screen colonoscopy 3-5 year . Patients sequentially 1:1 randomly allocate placebo Eviendep baseline ( T0 ) . The dietary supplement administer twice day 60 day advance screen colonoscopy , thus cover approximately eight complete colon epithelial turnover occur . Five day advance T60 colonoscopy , patient refrain fresh cook fruit vegetable intake . Bowel cleanse achieve PEG 4000 oral administration ( 1120 g/4 L water solution ) . N=8 biopsy samples/patient collect non adenomatous mucosa sigmoidal colon . Small polyp ( diameter less equal 0.5 cm ) topically electrocoagulated , whereas villous tubulovillous polyp ( diameter equal high 0.5 cm ) submit histological assessment .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Men woman , age : 5070 year Menopausal woman since least 2 year Diagnosed since 2003 adenoma , underwent polypectomy histological assessment Regularly inscribe actively ongoing surveillance program followup adenoma recurrence progression advance adenoma Screening colonoscopy every 35 year No previous concomitant administration ASA NSAIDs No previous concomitant administration Hormonal Replacement Therapy ( HRT ) No previous concomitant administration phytoestrogens Chronic inflammatory intestinal disease Intestinal and/or extraintestinal malignant neoplasm Acute chronic renal disease Anemia Coagulation disorder , BMI &gt; 30 Systemic corticosteroid Anticoagulants platelet antiaggregants Antibiotics within 30 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Non adenomatous mucosa</keyword>
	<keyword>Estrogen Receptor beta apoptosis</keyword>
	<keyword>Adenoma recurrence</keyword>
	<keyword>Screening colonoscopy every 3-5 year</keyword>
	<keyword>patient intermediate risk CRC</keyword>
</DOC>